BACKGROUND: Meningococcal disease is still a serious public health problem in many countries. A vaccine produced by Cuba was the first product against B meningococcus available on a large scale. In an attempt to control the increasing incidence of this serogroup in greater Rio de Janeiro, Brazil, the vaccine was used in 1990 in children aged 6 months-9 years. About 1.6 million children were vaccinated. METHODS: In order to assess the direct effectiveness of the vaccine in preventing disease, we conducted a case-control study during the first year after vaccination. Using a hospital-based census, we selected all children hospitalized with meningococcal disease and sampled the control group among children hospitalized with other types of meningitis. Vaccine effectiveness was estimated from the relationship, 1-OR, where OR (odds ratio) was the exponential of the logistic regression coefficient for the association between meningococcal disease and previous vaccination. RESULTS: A total of 275 cases and 279 controls were selected between September 1990 and October 1991. The summary adjusted measure of protection against serogroup B was 54% (95% confidence interval [CI]: 20-74%). Estimated protection varied among different age strata and place of residence, being high among children aged > or = 4 years, 71% (95% CI: 34-87%), and among those who lived in the City of Rio de Janeiro, 74% (95% CI: 42-89%). CONCLUSIONS: The results suggest that the vaccine produced by Cuba may offer protection against serogroup B meningococcal disease, but its effects may not be homogeneous.
BACKGROUND:Meningococcal disease is still a serious public health problem in many countries. A vaccine produced by Cuba was the first product against B meningococcus available on a large scale. In an attempt to control the increasing incidence of this serogroup in greater Rio de Janeiro, Brazil, the vaccine was used in 1990 in children aged 6 months-9 years. About 1.6 million children were vaccinated. METHODS: In order to assess the direct effectiveness of the vaccine in preventing disease, we conducted a case-control study during the first year after vaccination. Using a hospital-based census, we selected all children hospitalized with meningococcal disease and sampled the control group among children hospitalized with other types of meningitis. Vaccine effectiveness was estimated from the relationship, 1-OR, where OR (odds ratio) was the exponential of the logistic regression coefficient for the association between meningococcal disease and previous vaccination. RESULTS: A total of 275 cases and 279 controls were selected between September 1990 and October 1991. The summary adjusted measure of protection against serogroup B was 54% (95% confidence interval [CI]: 20-74%). Estimated protection varied among different age strata and place of residence, being high among children aged > or = 4 years, 71% (95% CI: 34-87%), and among those who lived in the City of Rio de Janeiro, 74% (95% CI: 42-89%). CONCLUSIONS: The results suggest that the vaccine produced by Cuba may offer protection against serogroup B meningococcal disease, but its effects may not be homogeneous.
Entities:
Keywords:
Age Factors; Americas; Bacterial And Fungal Diseases; Biology; Brazil; Caribbean; Case Control Studies; Cerebrovascular Effects; Child; Cuba; Demographic Factors; Developing Countries; Diseases; Evaluation; Evaluation Report; Infections; Latin America; North America; Physiology; Population; Population Characteristics; Research Methodology; South America; Studies; Urban Population; Vaccines; Youth
Authors: Dominique Boutriau; Jan Poolman; Ray Borrow; Jamie Findlow; Javier Diez Domingo; Joan Puig-Barbera; José María Baldó; Victoria Planelles; Angels Jubert; Julia Colomer; Angel Gil; Karin Levie; Anne-Diane Kervyn; Vincent Weynants; Francisco Dominguez; Ramon Barberá; Franklin Sotolongo Journal: Clin Vaccine Immunol Date: 2006-10-25
Authors: Luciete A Silva; Beatriz Coronato; Jessica Schlackman; Jane W Marsh; Chinelo Ezeonwuka; Andréia C L Fernandes; Victor C Souza; Lirna S da Silva; Elaine F Q de Amorim; Felipe G Naveca; Bernardino C de Albuquerque; Alcirene Amaral; Ana L S Souza; Filipe A Carvalho-Costa; Mustapha M Mustapha; Lee H Harrison; David E Barroso Journal: Infect Dis (Lond) Date: 2018-04-06
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822